JP2003512474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003512474A5 JP2003512474A5 JP2001533153A JP2001533153A JP2003512474A5 JP 2003512474 A5 JP2003512474 A5 JP 2003512474A5 JP 2001533153 A JP2001533153 A JP 2001533153A JP 2001533153 A JP2001533153 A JP 2001533153A JP 2003512474 A5 JP2003512474 A5 JP 2003512474A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- radiation exposure
- neutropenia
- thrombocytopenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 208000001647 Renal Insufficiency Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 201000006370 kidney failure Diseases 0.000 description 6
- 208000004235 neutropenia Diseases 0.000 description 6
- 206010043554 thrombocytopenia Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 230000006472 autoimmune response Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- CWVMWSZEMZOUPC-JUAXIXHSSA-N (3s,5s,8r,9s,10s,13s,14s,16r)-16-bromo-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](Br)C4)=O)[C@@H]4[C@@H]3CC[C@H]21 CWVMWSZEMZOUPC-JUAXIXHSSA-N 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 description 2
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 2
- QADHLRWLCPCEKT-LOVVWNRFSA-N androst-5-ene-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- CXGDRQWRJUSSAR-XKYJBRGQSA-N (3r,5s,8r,9s,10s,13s,14s,16r,17s)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene-3,16,17-triol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CC[C@H]21 CXGDRQWRJUSSAR-XKYJBRGQSA-N 0.000 description 1
- CXGDRQWRJUSSAR-KMDKCDOHSA-N (3s,5s,8r,9s,10s,13s,14s,16s,17r)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene-3,16,17-triol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H]([C@@H](O)C4)O)[C@@H]4[C@@H]3CC[C@H]21 CXGDRQWRJUSSAR-KMDKCDOHSA-N 0.000 description 1
- QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16145399P | 1999-10-25 | 1999-10-25 | |
| US60/161,453 | 1999-10-25 | ||
| PCT/US2000/026771 WO2001030802A2 (en) | 1999-10-25 | 2000-09-28 | Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003512474A JP2003512474A (ja) | 2003-04-02 |
| JP2003512474A5 true JP2003512474A5 (enExample) | 2007-11-29 |
Family
ID=22581233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001533153A Pending JP2003512474A (ja) | 1999-10-25 | 2000-09-28 | 血液細胞欠乏症の治療処置 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1223941B1 (enExample) |
| JP (1) | JP2003512474A (enExample) |
| AT (1) | ATE413179T1 (enExample) |
| AU (3) | AU782736B2 (enExample) |
| CA (1) | CA2388939C (enExample) |
| DE (1) | DE60040753D1 (enExample) |
| WO (1) | WO2001030802A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6667299B1 (en) | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US20060079492A1 (en) | 1999-10-25 | 2006-04-13 | Ahlem Clarence N | Compositions and treatment methods |
| US20070129282A1 (en) | 1998-11-24 | 2007-06-07 | Ahlem Clarence N | Pharmaceutical treatments and compositions |
| EP1228083A2 (en) | 1999-09-30 | 2002-08-07 | Hollis-Eden Pharmaceuticals Inc. | Therapeutic treatment of androgen receptor driven conditions |
| US7163918B2 (en) | 2000-08-22 | 2007-01-16 | New River Pharmaceuticals Inc. | Iodothyronine compositions |
| EP1372664A1 (en) * | 2001-03-01 | 2004-01-02 | Hollis-Eden Pharmaceuticals Inc. | Use of certain steroids for treatment of blood cell deficiencies |
| US20040138187A1 (en) * | 2002-08-28 | 2004-07-15 | Reading Christopher L. | Therapeutic treatment methods |
| US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
| US20050101581A1 (en) | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
| WO2004089304A2 (en) | 2003-04-01 | 2004-10-21 | Hollis-Eden Pharmaceuticals, Inc. | Antiandrogens with marginal agonist activity and methods of use |
| US7910755B2 (en) | 2004-09-29 | 2011-03-22 | Harbor Biosciences, Inc. | Stem cell expansion and uses |
| EP2471536A1 (en) * | 2004-09-29 | 2012-07-04 | Harbor BioSciences, Inc. | Steroid analogs and characterization and treatment methods |
| JP4839021B2 (ja) * | 2005-06-10 | 2011-12-14 | 国立大学法人 岡山大学 | 白血球及び／又は造血幹・前駆細胞動員剤 |
| US8217025B2 (en) | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
| US8354396B2 (en) | 2006-11-17 | 2013-01-15 | Harbor Therapeutics, Inc. | Drug identification and treatment method |
| US8486926B2 (en) | 2006-11-17 | 2013-07-16 | Harbor Therapeutics, Inc. | Steroid tetrol solid state forms |
| DK2273994T3 (en) | 2008-04-03 | 2016-02-01 | Neurmedix Inc | PHARMACEUTICAL FORMS OF A MEDICINE |
| AU2009256009B2 (en) | 2008-06-06 | 2014-02-06 | Neurmedix, Inc. | Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds |
| US20110190323A1 (en) | 2008-08-28 | 2011-08-04 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses thereof |
| WO2013142186A1 (en) * | 2012-03-21 | 2013-09-26 | Dana-Farber Cancer Institute, Inc. | Isolation and use of human lymphoid organ-derived suppressive stromal cells |
| WO2015100420A1 (en) | 2013-12-24 | 2015-07-02 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| EP3294298A4 (en) | 2015-05-08 | 2018-10-17 | President and Fellows of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
| WO2017004411A1 (en) | 2015-07-01 | 2017-01-05 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| US10836788B2 (en) | 2019-02-05 | 2020-11-17 | SD Chem, Inc. | Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL99772C (enExample) * | ||||
| US4602008A (en) * | 1984-12-14 | 1986-07-22 | Progenics, Inc. | Alkylated etiocholanolones and use as an anti-diabetic, anti-obesity and erythropoietic agent |
| FR2696934B1 (fr) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| EP0801557B1 (en) * | 1995-10-12 | 2003-07-02 | Supergen, Inc. | Liposome formulations of 5beta steroids |
| CA2237023C (en) * | 1995-11-13 | 2008-02-19 | Supergen, Inc. | Improved formulation for administration of steroid compounds |
| GB9708716D0 (en) * | 1997-04-29 | 1997-06-18 | Imperial College | Chronic heart failure |
| ATE269086T1 (de) * | 1998-03-06 | 2004-07-15 | Univ Brigham Young | Antibiotische steroidderivate |
-
2000
- 2000-09-28 CA CA002388939A patent/CA2388939C/en not_active Expired - Fee Related
- 2000-09-28 DE DE60040753T patent/DE60040753D1/de not_active Expired - Lifetime
- 2000-09-28 WO PCT/US2000/026771 patent/WO2001030802A2/en not_active Ceased
- 2000-09-28 AU AU79880/00A patent/AU782736B2/en not_active Ceased
- 2000-09-28 AT AT00970511T patent/ATE413179T1/de not_active IP Right Cessation
- 2000-09-28 JP JP2001533153A patent/JP2003512474A/ja active Pending
- 2000-09-28 EP EP00970511A patent/EP1223941B1/en not_active Expired - Lifetime
-
2005
- 2005-11-23 AU AU2005237117A patent/AU2005237117B2/en not_active Ceased
-
2008
- 2008-12-04 AU AU2008255138A patent/AU2008255138B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003512474A5 (enExample) | ||
| ES3030999T3 (en) | Elafibranor for use in the treatment of primary biliary cholangitis | |
| EP0906106B1 (en) | Prevention and treatment of colonic adenoma or colonic microadenoma by 6-fluoroursodeoxycholic acid (6-fudca) | |
| JP2023002544A5 (enExample) | ||
| JP2002519434A5 (enExample) | ||
| JP2011517683A5 (enExample) | ||
| JPWO2019107530A1 (ja) | 炎症性腸疾患の治療薬 | |
| EP1326636A2 (fr) | Composition vaccinale | |
| WO1994022896A1 (fr) | Ameliorant de la cholestase | |
| CN118593690B (zh) | 一种促进子宫内膜损伤修复的蛋白溶液及其应用 | |
| JPWO2013018837A1 (ja) | 左室拡張機能改善剤 | |
| TWI320711B (en) | Cathartic composition | |
| RU95118123A (ru) | Стероиды с 17-спирометилен-лактоновой или -лактольной группой | |
| JPH1036365A5 (enExample) | ||
| WO1999009992A1 (en) | Neovascularization promoters | |
| JPWO2019200005A5 (enExample) | ||
| JP2005504776A5 (enExample) | ||
| Unger et al. | Hepatitis B in chronic kidney disease: moving toward effective prevention | |
| JP2003532737A5 (enExample) | ||
| JP2015520759A5 (enExample) | ||
| JP2002539135A5 (enExample) | ||
| WO2022213870A1 (zh) | 通过口服给药抑制CD4+Treg细胞的药物和方法 | |
| JP2609479B2 (ja) | カリウム排泄剤 | |
| JPH04134030A (ja) | 徐放性モルヒネ直腸投与製剤 | |
| JPH07267867A (ja) | 抗内毒素作用を有する治療用薬剤 |